Global Organ Transplant Immunosuppressant Drugs Market: Regional Analysis

On the basis of region, the global Organ Transplant Immunosuppressant Drugs Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Increasing cases of kidney disorders in the U.S. is expected to propel growth of the organ transplant immunosuppressant drugs market in North America. For instance, according to the United Network for Organ Sharing (UNOS), in 2016, 19,061 kidney transplants were performed in the U.S. compared to 17,878 kidney transplants in 2015. Therefore, the number of kidney transplants increased by 6.6% in 2016.

Immunosuppressant is a drug used to suppress immune responses through various mechanisms. It is used in organ transplant to prevent the body from recognizing or attacking the transplanted organ. Immunosuppressant drugs can act by preventing and treating graft-versus-host disease and can minimize destruction of affected tissues in autoimmune and inflammatory diseases. There are two types of immunosuppressant drugs: induction drugs and maintenance drugs. Induction drugs are antirejection medicines that are used during the transplant, whereas maintenance drugs are antirejection medicines intended to use for long term.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2495

Global Organ Transplant Immunosuppressant Drugs Market: Drivers

Increasing number of patients that require organ transplants is expected to boost the organ transplant immunosuppressant drugs market. For instance, according to the U.S. Government Information on Organ Donation and Transplantation, U.S. Department of Health & Human Services, in 2017, 34770 organ transplants were performed in the U.S. and over 114000 patients were in need for organ transplantation.

Moreover, increasing approval for new products is expected to boost the organ transplant immunosuppressant drugs market growth. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) approved Thymoglobulin (anti-thymocyte globulin (rabbit) produced by Sanofi. Thymoglobulin is intended to use in conjunction with concomitant immunosuppression in the prophylaxis and prevention of acute rejection in patients receiving a kidney transplant.

However, decreasing number of organ transplantation due to shortage of organs may hinder growth for the organ transplant immunosuppressant drugs market. For instance, according to National Center for Biotechnology Information (NCBI), in 2015, only 30,973 organ transplants from 15,064 donors were performed in the U.S., while over 121,000 candidates were in need for organ transplantation.

Moreover, according to a report by Organ Donation and Transplantation Activity Report, the number of organ transplants decreased from 4,655 in 2013/14 to 4,431 in 2014/15 in the U.K.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/organ-transplant-immunosuppressant-drugs-market-2495

Moreover, increasing number of pipeline studies to develop drugs for organ transplant rejection is expected to contribute to growth of the market. For instance, in November 2018, Temple University, in collaboration with Veloxis Pharmaceuticals, initiated phase 4 clinical trial for Tacrolimus Extended Release Oral Tablet to evaluate dosing strategies for de novo once-daily extended release tacrolimus (LCPT) in kidney transplant recipients. The study is expected to be completed by August 2019.

Europe is expected to witness significant growth in the market over the forecast period. The growth is attributed to increasing product launch by key players in this region. For instance, in 2013, Roche Group launched two new highly-sensitive therapeutic drug monitoring tests for immunosuppressant medicines – tacrolimus and cyclosporine worldwide (except U.S.). Therapeutic monitoring for immunosuppressive drugs is a major part of transplant medicine and is crucial for maintaining the health of patients with organ transplantation for longer period.

Key player operating in the organ transplant immunosuppressant drugs market include, Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2495

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737